Aptevo Therapeutics Inc. (APVO) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $-30,945.60 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-84.67 vs est $-30,945.60 (beat +99.7%). 2025: actual $-87.27 vs est $-87.27 (beat +0%). Analyst accuracy: 0%.
APVO Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Aptevo Therapeutics Inc. in the past 3 months
EPS Estimates — APVO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$84.67
vs Est –$30,945.60
▲ 36,448.5% off
2025
Actual –$87.27
vs Est –$87.27
▼ 0.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — APVO
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
